Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Japanese firms Ono Pharmaceutical and Chordia Therapeutics have agreed a licensing deal on CTX-177, the latter company’s MALT1 inhibitor and its related compounds. 15 December 2020
Biotechnology
Spanish pharma company Reig Jofre has reached an agreement with Janssen to execute the technology transfer to manufacture its investigational COVID-19 vaccine candidate, Ad26.COV2-S. 15 December 2020
Biotechnology
Research from industry analyst GlobalData has found that established players in Japan’s immunology market have a dominant lead in the digital marketing space. 15 December 2020
Biotechnology
The US Food and Drug Administration has approved a shorter two-hour infusion time for Ocrevus (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). 15 December 2020
Biotechnology
Shares of French metabolic diseases biotech company Poxel closed up 4.1% at 6.62 euros today, after it announced an update on results from the PXL770 Phase IIa STAMP-NAFLD trial in non-alcoholic steatohepatitis (NASH). 14 December 2020
Biotechnology
ADC Therapeutics and Hillhouse Capital-backed Overland Pharmaceuticals have jointly formed a new company. 14 December 2020
Biotechnology
A Phase III study of ruxolitinib in COVID-19 has missed its primary endpoint, with no statistically-significant reduction in severe cases of the disease. 14 December 2020
Biotechnology
Messenger ribonucleic acid (mRNA) specialist company CureVac has enrolled the first participant in the pivotal Phase IIb/III study of its vaccine candidate, CVnCoV, against COVID-19. 14 December 2020
Biotechnology
The UK life sciences industry has reiterated its commitment to the promise of cell and gene therapies, with representatives across the sector renewing commitments at the 11th Pharmaceutical Industry Network Group (PING) conference. 14 December 2020
Biotechnology
The US Food and Drug Administration late Friday issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. 12 December 2020
Biotechnology
Older adults achieved a lower immune response than hoped for in an early trial of Sanofi and GlaxoSmithKline’s coronavirus vaccine. 11 December 2020
Biotechnology
A key advisory panel of the US medicines regulator has voted in favor of providing Emergency Use Authorization (EUA) for BioNTech and Pfizer’s coronavirus vaccine. 11 December 2020
Biotechnology
Japanese drug major Chugai Pharmaceuticals has concluded a license agreement with Swiss giant Roche for the development and commercialization in Japan for the antibody cocktail of casirivimab and imdevimab (formerly known as REGN-COV2) for COVID-19. 11 December 2020
Biotechnology
AbbVie yesterday announced positive results from the Phase III induction study, U-ACHIEVE, which showed Rinvoq (upadacitinib) 45mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week eight, as well as all ranked secondary endpoints, in adult patients with moderate to severe ulcerative colitis. 11 December 2020
Biotechnology
Shares in French biotech Innate Pharma dropped 20% on Friday morning, after the firm announced it was handing back US and EU commercialization rights for Lumoxiti (moxetumomab pasudotox-tdfk). 11 December 2020
Biotechnology
Shares of X4 Pharmaceuticals closed down 2.56% at $6.10 yesterday, despite the company gaining a coveted regulatory designation for its lead drug candidate mavorixafor. 11 December 2020
Biotechnology
Swedish Orphan Biovitrum and Apellis Pharmaceuticals today announced positive top-line results at week 48 from the Phase III PEGASUS study, which demonstrated sustained hematological and clinical improvements in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were treated with pegcetacoplan, an investigational, targeted C3 therapy. 10 December 2020
Biotechnology
Clive Glover, director, strategy, Pall Corporation, provides an Expert View on what recent developments mean for the industry and the importance of safety in gene therapy manufacturing. 10 December 2020
Biotechnology
Swiss cancer giant Roche has presented an exploratory analysis from the Phase III IMvigor010 study of checkpoint blocker Tecentriq (atezolizumab) in muscle-invasive urothelial cancer (MIUC). 10 December 2020
Biotechnology
US biotech major Gilead Sciences seems to have an insatiable appetite for M&A this year, as it notches up a fifth acquisition deal today. 10 December 2020
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze